RxDoctor Payments Data

Margaret Brochocki

Psychiatric/Mental Health · de Pere, WINPI 1033722392

Payments from drug & device makers

$428in general payments, 2019–2025

Across 22 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$189
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$63
  • Axsome Therapeutics, Inc.$51
  • Otsuka America Pharmaceutical, Inc.$29
  • E.r. Squibb & Sons, L.L.C.$27
  • Neurocrine Biosciences, Inc.$23
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$35483%
  • Education$7417%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$428 in reported general payments places this provider in the 55th percentile of 384 psychiatric/mental health providers in Wisconsin.

See all psychiatric/mental health providers in Wisconsin

Medicare billing

Part B allowed, 2024
$38,183
Medicare patients
55
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate27$218,880
RexultiBrexpiprazole38$57,734
VraylarCariprazine Hcl33$53,055
EmsamSelegiline12$24,896
Aripiprazole108$18,742
VyvanseLisdexamfetamine Dimesylate29$13,043
QuviviqDaridorexant Hcl18$8,590
Lisdexamfetamine Dimesylate31$7,632
Desvenlafaxine Succinate ErDesvenlafaxine Succinate44$5,998
Divalproex Sodium ErDivalproex Sodium49$4,817
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine44$4,553
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine107$4,495
Varenicline Tartrate13$4,001
Quetiapine Fumarate142$3,973
Lamotrigine ErLamotrigine13$3,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$23$218,88027 claims
Otsuka America Pharmaceutical, Inc.Rexulti$29$57,73438 claims
AbbVieVraylar$189$53,05533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 384 psychiatric/mental health providers in Wisconsin.

Other psychiatric/mental health in de Pere

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →